Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Key facts

Study ID

NCT00687934

Run by

Synta Pharmaceuticals Corp.

People needed

53

Starts

2007-10-01

Expected to finish

2011-10-01

Last updated by the study team

2014-09-18

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be documented to be refractory or not candidates for current approved therapies.
• Must have an ECOG status 0-2.
• Peripheral neuropathy < or = 2.
• Must have acceptable organ and marrow function per protocol parameters.
• No clinically significant ventricular arrythmias or ischemia.

You may not qualify if…

• Must not be pregnant or breastfeeding.
• Chemotherapy or radiation within 3 weeks.
• Previous radiation to >25% of total bone marrow.
• Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation.
• Primary brain tumors or active brain metastases.
• Use of any investigational agents within 4 weeks.
• Treatment with chronic immunosuppressants.
• Uncontrolled, intercurrent illness.

Where it is running

• Premiere Oncology — Santa Monica, California, United States
• US Oncology Dayton Oncology and Hematology, P.A — Kettering, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.